|Bid||0.00 x 3200|
|Ask||0.00 x 2900|
|Day's Range||16.66 - 17.37|
|52 Week Range||16.56 - 69.76|
|Beta (3Y Monthly)||2.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.33|
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 15, 2019 and August 8, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before October 18, 2019. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge.
that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all investors that purchased Nektar Therapeutics, Inc. (NKTR) (the “Company”) securities between February 15, 2019 and August 8, 2019 (the "Class Period"), inclusive. Investors who purchased the shares of Nektar Therapeutics, Inc. are urged to contact the firm immediately at firstname.lastname@example.org or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.If you have incurred losses in the shares of Nektar Therapeutics, Inc., you may, no later than October 18, 2019, request that the Court appoint you lead plaintiff of the proposed class.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics from February 15, 2019 through August 8, 2019, inclusive .
NEW YORK, Aug. 20, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all investors that purchased Nektar Therapeutics, Inc. (NKTR) securities between February 15, 2019 and August 8, 2019 (the "Class Period"). Investors have until October 18, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit. On August 8, 2019, the company revealed that a manufacturing issue caused two batches of bempegaldesleukin to differ from the other twenty batches that were produced.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). Nektar investors have until October 18, 2019 to file a lead plaintiff motion. Investors suffering losses on their Nektar investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to email@example.com.
Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Damiba v. Nektar Therapeutics, et. al., (Case No. 3:19-cv-05173) on behalf of persons and/or entities that acquired Nektar Therapeutics (NASDAQ: NKTR) (“Nektar” or the “Company”) securities between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action.
NEW YORK , Aug. 15, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against Nektar Therapeutics, Inc. (NASDAQ: NKTR). Our investigation concerns whether Nektar has violated ...
NEW YORK , Aug. 14, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Nektar Therapeutics ("Nektar" or ...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Nektar admitted on August 8, 2019, that it had suffered manufacturing problems resulting in two batches of Bempegaldesleukin differing from the other 20 batches produced.
(Bloomberg) -- Investors sentiment on Nektar Therapeutics has soured as a manufacturing snafu raised concern about what had initially been seen as promising clinical data for its experimental cancer drug bempegaldesleukin.As Wall Street analysts continue to debate the drug’s potential, investors are fleeing fast. The stock fell 8% on Monday, bringing its two-day loss to 36%, or about $1.8 billion of market value. Nektar is now 2019’s worst performer in the S&P 500, after taking the top spot shortly after joining the benchmark last year.Some bulls have already backpedaled after the company also said it’s collaboration with Bristol-Myers Squibb Co. has narrowed to fewer studies, and lung cancer data won’t be presented at the ESMO conference in Barcelona next month.Nektar has seen three downgrades just last week, with the number of hold or equivalent ratings rising to a total of six. Eight other analysts who cover the stock stood by their bullish recommendations.The debate over bempegaldesleukin, formerly known as NKTR-214, is set to continue until the company reports first results from its late-stage studies, which are not expected until next year.To contact the reporter on this story: Tatiana Darie in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Richard RichtmyerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Nektar dropped 40% on Friday after announcing it had manufacturing issues in two batches of experimental cancer drugs.
Thursday's gain felt a little too strong to trust, and sure enough, it didn't last. The S&P 500 fell 0.66% on Friday, leaving it squarely in the middle of equally important support and resistance levels.Source: Shutterstock General Electric (NYSE:GE) was the proverbial problem child. It fell more than 3%, logging its seventh loss in eight sessions as worries about its turnaround resurfaced. Smaller Nektar Therapeutics (NASDAQ:NKTR) posted the decidedly larger loss though, giving up nearly 30% of its value after the company reported a production issue with one of the drugs in a key trial right now.One noteworthy winner … Amgen (NASDAQ:AMGN) rallied 6% on the heels of news it has won a case involving the patent on its Enbrel. There just weren't enough names like Amgen to finish the week on a high note.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Medical Marijuana Stocks to Cure Your Portfolio As the new trading week kicks off, take a closer look at the stock charts of News Corp (NASDAQ:NWSA), Xilinx (NASDAQ:XLNX) and Gilead Sciences (NASDAQ:GILD). They're all positioned for major moves, with just the right nudge. Gilead Sciences (GILD)For the better part of June and July, Gilead Sciences was working on a break above a couple of different resistance levels. Although they were tough, a move above them could mark the beginning of a prolonged move higher. Unfortunately, before that advance had a chance to fully take hold, it petered out in the latter part of July.It may be too soon to give up on GILD stock just yet though. Last week it found support at a (very) familiar spot, and in the meantime we've moved to within reach of what could prove to be a hugely catalytic technical event. * Click to EnlargeThe support is the floor that lines up all the key lows since the end of 2018, marked in white on both stock charts. Gilead shares pushed up and off that floor last week, ending the pullback. * Thanks to June's big jump following a broad rally effort since March, the purple 50-day moving average line is close to crossing above the white 200-day average … a so-called "golden cross" that may spur more buying. * The weekly chart puts things in perspective. The loss since 2015 has been significant. The same weekly chart shows the stock is also on the verge of breaking above a couple different long-term resistance lines driving that downtrend. One is marked in blue, and the other red, tagging all the key highs going back for years. Xilinx (XLNX)Xilinx shares have been fighting a losing battle since July 24, when a budding rally quickly rolled over and turned into a selloff. Broad concerns about trade with China and specific concerns about its relationship with Huawei up-ended the bullish effort.The selloff initially looked manageable. Although the dip wasn't small, shares hinted as if they would find support where they most needed to (and where they did the last time support was found). Thursday's sharp gain largely solidified the bullish backdrop. Friday's big stumble, however, may have cemented more weakness in place. * 10 Internet Stocks Getting Hammered * Click to EnlargeThe line in the sand is the 200-day moving average, plotted in white on both stock charts. XLNX broke that support in a big way on Friday, logging its lowest close in weeks to end the week. * The volume for the past two weeks is problematic for the bulls too. The selling has been on high volume, and the one good day in the midst of the rout -- Thursday -- was clearly on below average volume. * Last week's selling has also pulled Xilinx to within striking distance of a key Fibonacci retracement line near $102. It may not break it with a straight-line move, but it's still vulnerable to such a breakdown. News Corp (NWSA)It was wholly inspired by its fourth-quarter earnings beat. Nonetheless, News Corp shares demonstrated impressive technical strength on Friday, finding support where it ideally would. The big move carried shares to a huge line in the sand as well, and though it didn't push shares past that line, NWSA stock is perfectly positioned to punch through that mark this week. It may just need to peel back a little bit first to get a good running start. * Click to EnlargeThe line in question is right around $13.77, marked in yellow on both stock charts, near where NWSA peaked on Friday as well as in late June. * The rally, however, ultimately started on Wednesday with a hammer-shaped reversal bar that found technical support at the gray 100-day and white 200-day moving average lines. * It would be easy to overlook in the midst of the volatility, but the purple 50-day moving average line moves above the 200-day moving average last month, pointing to a well-established uptrend.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Large-Cap Stocks to Sell Right Now * 7 Stocks Under $7 to Invest in Now * 7 Marijuana Stocks With Critical Levels to Watch The post 3 Big Stock Charts for Monday: Xilinx, News Corp and Gilead Sciences appeared first on InvestorPlace.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ:NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Nektar admitted on August 8, 2019, that it had suffered manufacturing problems resulting in two batches of Bempegaldesleukin differing from the other 20 batches produced.
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) investors concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. On August 8, 2019, after the market closed, the Company revealed that a manufacturing issue caused two batches of bempegaldesleukin to differ from the other 20 batches that were produced.
Nektar Therapeutics stock crashed to a two-year low Friday after the biotech company revealed a manufacturing issue could have skewed the results of several cancer treatment studies.
Law Offices of Howard G. Smith announces an investigation on behalf of Nektar Therapeutics investors concerning the Company and its officers’ possible violations of federal securities laws.
Nektar Therapeutics (NASDAQ: NKTR) crashed more than 30% Friday after the company reported a huge second-quarter sales miss. Nektar also said manufacturing problems may have impacted the results of several studies of its NKTR-214 cancer treatment drug, which it has been testing in combination with Bristol-Myers Squibb (NYSE: BMY) drug Opdivo. On Friday, Benzinga Pro subscribers received options alerts related to two large Nektar option trades.
(Bloomberg Opinion) -- The drug industry is rarely dull, but this week took things to another level.Things kicked off Tuesday with the Food and Drug Administration’s unusual revelation that Novartis AG had delayed disclosing manipulated data related to early animal tests of its $2.1 billion gene therapy Zolgensma. While the drug is still considered safe, the lapse sparked a decline in Novartis shares. A couple of days later, a wild Thursday afternoon created broader biotech turmoil. Amarin Corp.’s stock plunged after it revealed an unexpected delay in the FDA review of new data for its fish oil-derived heart drug Vascepa. Nektar Therapeutics followed by disclosing a manufacturing issue for its key cancer drug that may have impacted trial results. Its shares tanked more than 30% Friday.Investing in biotechnology can be a tricky business. Stock buyers typically focus on clinical-trial readouts or shifts in drug pricing and health policy, but a whole host of other things can go wrong. Good management and transparency can make things smoother. In the case of this week’s stumbles, spin from company leaders made things worse. Novartis’s reputation still suffers from an earlier effort to seemingly buy White House access via former Trump fixer Michael Cohen. That should have encouraged the company to err on the side of transparency when it discovered this data issue in March, and let regulators and the public know as soon as possible. Instead, Novartis decided to complete a rather slow internal investigation and didn’t inform the FDA until after the drug was approved two months later.The data in question came from a test in mice that is no longer in use. Patient safety wasn’t affected, and the drug will rightfully stay on the market. But the FDA relies on drugmakers to provide clean data, especially for drugs like Zolgensma that are on an accelerated path to approval. Breaking that trust is a big deal for a company of this size, and the FDA was understandably livid about the way this was handled. CEO Vas Narasimhan held a conference call and analyst Q&A after the issue became public, but spent much of it defensively downplaying the problem. He didn’t do nearly enough to fix his relationship with the agency or boost investor trust. The problem escalated on Friday after a group of Senators wrote a letter to the FDA blasting Novartis and urging action. Amarin’s issue wasn’t withholding information from the FDA, but putting words in its mouth. The company said late last month that it believed it was unlikely that the FDA would choose to convene an expert panel to review Vascepa’s ability to cut the risk of heart attacks and strokes. That wasn’t entirely unreasonable as the FDA’s target date for marketing approval on Amarin’s new data was less than two months away. But the FDA sets those dates and can change them. Amarin disclosed Thursday that the agency wants to convene a panel in November after all. That will likely delay approval until at least December. The panel may go swimmingly, and this may be only a minor delay. But investor expectations would have been better calibrated if Amarin hadn’t publicly made risky assumptions. Nektar’s situation is the strangest of all. On its second-quarter conference call Thursday, management revealed that the company was curious about why some patients weren’t responding as well to its cancer drug bempegaldesleukin. After examining early drug lots used in trials, it found variations in two batches. Nektar said it’s rebuilding its quality-control strategy as a result, which is a good idea; its decision to try to spin a flub that may have harmed patients into an upside case for its medicine wasn’t. The company spent a chunk of its second-quarter call elaborating a confusing post-hoc analysis of the impact of different drug batches. As you might imagine, the way they sliced the data suggests that its drug might have looked more promising if it weren’t for those bad batches. The analysis split already small trials into even smaller new subgroups, which makes the data difficult to interpret. Only a new trial will give investors data they can actually trust. In short, Nektar’s attempt at clarification only muddied the waters. When confronted with bad news or uncertainty, the desire to spin it is natural. Drugmakers would be wise to resist that urge. When the truth comes out, it just makes the backlash bigger. To contact the author of this story: Max Nisen at email@example.comTo contact the editor responsible for this story: Beth Williams at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
MILWAUKEE , Aug. 9, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating possible securities fraud claims against Nektar (Nasdaq: NKTR) resulting from inaccurate statements Nektar made regarding ...
Amarin shares are plunging after the biotech company revealed the FDA will proceed with a review of its heart drug. This coming as Nektar Therapeutics is sliding after it disclosed a quality control issue with a key cancer therapy. Yahoo Finance's Jared Blikre joins Akiko Fujita on 'The Ticker' to discuss.